Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
Pharmex Middle EastPharmex Middle East
Not Confirmed
Not Confirmed
26-28 May, 2026
Not Confirmed
Not Confirmed
27-28 May, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PEGS Boston Summit
Not Confirmed
Contact SupplierPEGS Boston Summit
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
Pharmex Middle EastPharmex Middle East
Industry Trade Show
Not Confirmed
26-28 May, 2026
Industry Trade Show
Not Confirmed
27-28 May, 2026
Digital content
NEWS #PharmaBuzz
20 May 2026
// ECONOMICTIMES
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bayer-bets-big-on-self-care-market-to-deepen-india-play/articleshow/131210006.cms
18 May 2026
// REUTERS
https://www.reuters.com/legal/litigation/bayer-agrees-pay-133-million-pcb-cleanup-two-states-2026-05-18/
12 May 2026
// ENDPOINTS
https://endpoints.news/bayer-to-make-careful-but-aggressive-return-to-pharma-ma-ceo-says/
07 May 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/05/07/3289955/0/en/askbio-announces-6-presentations-at-american-society-of-gene-and-cell-therapy-asgct-29th-annual-meeting.html
06 May 2026
// PHARMIWEB
https://www.pharmiweb.com/press-release/2026-05-06/bayer-to-acquire-perfuse-therapeutics-to-complement-ophthalmology-pipeline
04 May 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/05/04/3286590/0/en/bridgebio-to-present-new-acoramidis-data-on-disease-progression-biomarkers-and-clinical-outcomes-at-esc-heart-failure-2026.html
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Click Us!
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-07-11
Pay. Date : 2013-07-05
DMF Number : 1985
Submission : 1972-08-16
Status : Active
Type : II
Certificate Number : R1-CEP 1996-079 - Rev 07
Issue Date : 2017-03-03
Type : Chemical
Substance Number : 140
Status : Valid
Registration Number : 218MF10829
Registrant's Address : Kaiser-Wilhelm-Allee 1,51373 Leverkusen, Germany
Initial Date of Registration : 2006-10-20
Latest Date of Registration :
NDC Package Code : 12866-1016
Start Marketing Date : 2017-05-10
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-02-05
Pay. Date : 2013-01-28
DMF Number : 2726
Submission : 1976-08-05
Status : Active
Type : II
Certificate Number : R1-CEP 2013-050 - Rev 00
Issue Date : 2018-07-23
Type : Chemical
Substance Number : 234
Status : Valid
Registration Number : 219MF10281
Registrant's Address : Kaiser-Wilhelm-Allee 1,51373 Leverkusen, Germany
Initial Date of Registration : 2007-09-10
Latest Date of Registration :
NDC Package Code : 12866-1013
Start Marketing Date : 2017-05-13
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3379
Submission : 1978-11-02
Status : Active
Type : II
Registration Number : 222MF10134
Registrant's Address : Kaiser-Wilhelm-Allee 1,51373 Leverkusen, Germany
Initial Date of Registration : 2010-04-13
Latest Date of Registration :
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12138
Submission : 1996-09-09
Status : Active
Type : II
Certificate Number : R1-CEP 2009-070 - Rev 02
Issue Date : 2022-07-27
Type : Chemical
Substance Number : 2404
Status : Valid
Registrant Name : Bayer Korea Co., Ltd.
Registration Date : 2006-03-02
Registration Number : 309-2-ND
Manufacturer Name : Bayer AG@[Micro-process Manufacturer] Bayer AG
Manufacturer Address : Ernst-Schering-Straße 14 59192 Bergkamen, Germany@Max-Dohrn-Straße 8 10589 Berlin, Germany
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-01-28
Pay. Date : 2013-01-08
DMF Number : 4684
Submission : 1982-10-13
Status : Active
Type : II
Certificate Number : R2-CEP 1995-017 - Rev 04
Issue Date : 2017-03-01
Type : Chemical
Substance Number : 821
Status : Valid
NDC Package Code : 12866-1018
Start Marketing Date : 2017-05-12
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Hyundai Pharmaceutical Co., Ltd.
Registration Date : 2020-04-01
Registration Number : 20121228-181-I-166-03(2)
Manufacturer Name : Bayer AG "Bergkamen"@Bayer AG "Berlin-Charlottenburg"
Manufacturer Address : Ernst-Schering-Straße 14, 59192 Bergkamen, Germany@Max-Dohrn-Straße 8, 10589 Berlin, Germany
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13061
Submission : 1998-07-07
Status : Active
Type : II
Certificate Number : CEP 2017-275 - Rev 02
Issue Date : 2023-12-06
Type : Chemical
Substance Number : 2735
Status : Valid
Registrant Name : Bayer Korea Co., Ltd.
Registration Date : 2004-11-05
Registration Number : 309-1-ND
Manufacturer Name : Bayer AG@Dynamit Nobel GmbH Explosivstoff- und Systemtechnik
Manufacturer Address : Ernst-Schering-Straße 14 59192 Bergkamen, Germany@Kalkstraße 218 51377 Leverkusen Germany
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-01-28
Pay. Date : 2013-01-08
DMF Number : 4178
Submission : 1981-05-21
Status : Active
Type : II
Certificate Number : R1-CEP 2000-101 - Rev 03
Issue Date : 2017-03-03
Type : Chemical
Substance Number : 926
Status : Valid
NDC Package Code : 12866-1010
Start Marketing Date : 2017-05-10
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-10-04
Pay. Date : 2013-09-30
DMF Number : 2033
Submission : 1972-12-22
Status : Active
Type : II
Certificate Number : R1-CEP 2000-111 - Rev 04
Issue Date : 2017-06-22
Type : Chemical
Substance Number : 850
Status : Valid
NDC Package Code : 12866-1014
Start Marketing Date : 2017-05-12
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21580
Submission : 2008-07-23
Status : Active
Type : II
Certificate Number : R0-CEP 2021-090 - Rev 00
Issue Date : 2023-02-22
Type : Chemical
Substance Number : 2932
Status : Valid
NDC Package Code : 12527-0580
Start Marketing Date : 2014-05-01
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Bayer Korea Co., Ltd.
Registration Date : 2008-06-27
Registration Number : Su2420-3-ND
Manufacturer Name : [Processes other than micronization (Rivaroxaban manufacturing)] Bayer AG@[Micronization Plant ①] Bayer AG@[Micronization Plant ②] Bayer HealthCare Manufacturing Srl
Manufacturer Address : [Microlysis and other processes (Rivaroxaban manufacturing)] Werksteil Elberfeld Friedrich-Ebert-Straße 217-333 42117 Wuppertal Germany @ [Microlysis Plant ①] 51368 leverkusen @ [Microlysis Plant ②] Via delle Groane 126 20024 Garbagnate Milanese, Italy
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-01-30
Pay. Date : 2013-01-10
DMF Number : 15077
Submission : 2000-10-02
Status : Active
Type : II
Certificate Number : R1-CEP 2000-109 - Rev 04
Issue Date : 2020-05-28
Type : Chemical
Substance Number : 1373
Status : Valid
NDC Package Code : 12866-1175
Start Marketing Date : 2017-05-15
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Oxymetazoline HCl is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of nasal obstruction.
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 12, 2026
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oxymetazoline HCl is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of nasal obstruction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 12, 2026
Details:
Under the acquisition of PER-001, undisclosed company targets the endothelin pathway to address open-angle glaucoma.
Lead Product(s): PER-001
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Recipient: Perfuse Therapeutics
Deal Size: $2,450.0 million Upfront Cash: $300.0 million
Deal Type: Acquisition May 06, 2026
Lead Product(s) : PER-001
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Recipient : Perfuse Therapeutics
Deal Size : $2,450.0 million
Deal Type : Acquisition
Bayer Acquires Perfuse Therapeutics to Expand Ophthalmology Pipeline
Details : Under the acquisition of PER-001, undisclosed company targets the endothelin pathway to address open-angle glaucoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $300.0 million
May 06, 2026
Details:
AB-1005 (Ametefgene Parvec) is a cell & gene therapy drug, which is currently being evaluated in Phase II clinical studies for the treatment of parkinson disease.
Lead Product(s): Ametefgene Parvec
Therapeutic Area: Neurology Brand Name: AB-1005
Study Phase: Phase IIProduct Type: Cell & Gene Therapy
Recipient: Bayer AG
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 05, 2026
A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease
Details : AB-1005 (Ametefgene Parvec) is a cell & gene therapy drug, which is currently being evaluated in Phase II clinical studies for the treatment of parkinson disease.
Product Name : AB-1005
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 05, 2026
Details:
BAY 3771249 is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of colorectal neoplasms.
Lead Product(s): BAY 3771249,Cetuximab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 16, 2026
Details : BAY 3771249 is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of colorectal neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 16, 2026
Details:
Nurandociguat is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of renal insufficiency, chronic.
Lead Product(s): Nurandociguat,Rosuvastatin Calcium,Dabigatran Etexilate Mesylate
Therapeutic Area: Nephrology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 07, 2026
Lead Product(s) : Nurandociguat,Rosuvastatin Calcium,Dabigatran Etexilate Mesylate
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nurandociguat is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of renal insufficiency, chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 07, 2026
Details:
Darolutamide is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of prostatic neoplasms.
Lead Product(s): Darolutamide,Goserelin Acetate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 04, 2026
Lead Product(s) : Darolutamide,Goserelin Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Darolutamide is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of prostatic neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 04, 2026
Details:
Nitroglycerin is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of coronary artery disease.
Lead Product(s): Nitroglycerin,Nurandociguat
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 24, 2026
Lead Product(s) : Nitroglycerin,Nurandociguat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nitroglycerin is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of coronary artery disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 24, 2026
Details:
Under the acquisition of Iloprost Trometamol, a HPAPI, the deal aims to advance treatment for primary pulmonary hypertension through targeting the Prostanoid IP receptor.
Lead Product(s): Iloprost Trometamol
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: HPAPI
Sponsor: Essential Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 17, 2026
Lead Product(s) : Iloprost Trometamol
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Essential Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Essential Pharma strengthens rare disease portfolio with acquisition of Ventavis® (iloprost trome...
Details : Under the acquisition of Iloprost Trometamol, a HPAPI, the deal aims to advance treatment for primary pulmonary hypertension through targeting the Prostanoid IP receptor.
Product Name : Undisclosed
Product Type : HPAPI
Upfront Cash : Undisclosed
February 17, 2026
Details:
Aflibercept is a protein drug, which is currently being evaluated in Phase III clinical studies for the treatment of polypoidal choroidal vasculopathy.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Protein
Recipient: Yeungnam University College of Medicine
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 05, 2026
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : Yeungnam University College of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Aflibercept is a protein drug, which is currently being evaluated in Phase III clinical studies for the treatment of polypoidal choroidal vasculopathy.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 05, 2026
Details:
Aflibercept is a protein drug, which is currently being evaluated in Phase IV clinical studies for the treatment of polypoidal choroidal vasculopathy.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Protein
Recipient: Shanghai General Hospital
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 26, 2026
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Recipient : Shanghai General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Aflibercept is a protein drug, which is currently being evaluated in Phase IV clinical studies for the treatment of polypoidal choroidal vasculopathy.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 26, 2026
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients
Inspections and registrations
ABOUT THIS PAGE
BAYER is a supplier offers 56 products (APIs, Excipients or Intermediates).
Find Ethinyl Estradiol bulk with DMF, CEP, JDMF offered by BAYER
Find Norethisterone bulk with DMF, CEP, JDMF offered by BAYER
Find Acarbose bulk with DMF, CEP offered by BAYER
Find CAS 50-28-2 bulk with DMF, JDMF offered by BAYER
Find Ciprofloxacin bulk with DMF, CEP offered by BAYER
Find Ciprofloxacin Hydrochloride bulk with DMF, CEP offered by BAYER
Find Drospirenone bulk with DMF, CEP offered by BAYER
Find Estradiol bulk with DMF, CEP offered by BAYER
Find Gadobutrol bulk with DMF, CEP offered by BAYER
Find Iopromide bulk with DMF, CEP offered by BAYER
Find Levonorgestrel bulk with DMF, CEP offered by BAYER
Find Medroxyprogesterone Acetate bulk with DMF, CEP offered by BAYER
Find Norethisterone Acetate bulk with DMF, CEP offered by BAYER
Find Rivaroxaban bulk with DMF, CEP offered by BAYER
Find Testosterone bulk with DMF, CEP offered by BAYER
Find Testosterone Enanthate bulk with DMF, CEP offered by BAYER
Find Alpha-Cyclodextrin bulk with DMF offered by BAYER
Find Aspirin bulk with CEP offered by BAYER
Find Azelaic Acid bulk with DMF offered by BAYER
Find Ciprofloxacin bulk with DMF offered by BAYER
Find Clotrimazole bulk with CEP offered by BAYER
Find Cyproterone Acetate bulk with CEP offered by BAYER
Find Dienogest bulk with DMF offered by BAYER
Find Estradiol Valerate bulk with CEP offered by BAYER
Find Estriol bulk with CEP offered by BAYER
Find Etofenamate bulk with CEP offered by BAYER
Find Gadolinium Ethoxybenzyl Dtpa bulk with DMF offered by BAYER
Find Gestodene bulk with CEP offered by BAYER
Find Hydrocortisone bulk with CEP offered by BAYER
Find Iloprost bulk with DMF offered by BAYER
Find Iopromide bulk with CEP offered by BAYER
Find Levonorgestrel bulk with DMF offered by BAYER
Find Mesalazine bulk with JDMF offered by BAYER
Find Molidustat bulk with DMF offered by BAYER
Find Moxifloxacin Hydrochloride bulk with CEP offered by BAYER
Find Nifedipine bulk with CEP offered by BAYER
Find Norethisterone bulk with CEP offered by BAYER
Find Rivaroxaban bulk with DMF offered by BAYER
Find Testosterone bulk with CEP offered by BAYER
Find Testosterone Undecanoate bulk with DMF offered by BAYER
Find Nisoldipine bulk offered by BAYER
Find Ciprofloxacin Hydrochloride bulk offered by BAYER
Find Enrofloxacin bulk offered by BAYER
Find Estradiol bulk offered by BAYER
Find Estradiol Benzoate bulk offered by BAYER
Find Estradiol Valerate bulk offered by BAYER
Find Ethinyl Estradiol bulk offered by BAYER
Find Finerenone bulk offered by BAYER
Find Methylprednisolone Aceponate bulk offered by BAYER
Find Moxifloxacin bulk offered by BAYER
Find Nifedipine bulk offered by BAYER
Find Pentetic Acid bulk offered by BAYER
Find Pradofloxacin bulk offered by BAYER
Find Regorafenib bulk offered by BAYER
Find Sorafenib bulk offered by BAYER
Find Berrysiguat bulk offered by BAYER
Share 
